Related references
Note: Only part of the references are listed.A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
Sang Joon Shin et al.
INVESTIGATIONAL NEW DRUGS (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Amir Abdollahi et al.
DRUG RESISTANCE UPDATES (2010)
Hallmarks of cancer: Interactions with the tumor stroma
Kristian Pietras et al.
EXPERIMENTAL CELL RESEARCH (2010)
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
M. P. Smerdel et al.
GYNECOLOGIC ONCOLOGY (2010)
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
Ernest S. Han et al.
GYNECOLOGIC ONCOLOGY (2010)
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
Angelica Calleri et al.
CLINICAL CANCER RESEARCH (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
David Loven et al.
ACTA ONCOLOGICA (2008)
Clinical biomarkers of angiogenesis inhibition
Aaron P. Brown et al.
CANCER AND METASTASIS REVIEWS (2008)
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Russell J. Schilder et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
Lukas A. Hefler et al.
GYNECOLOGIC ONCOLOGY (2006)
Predicting benefit from anti-angiogenic agents in malignancy
Adrian M. Jubb et al.
NATURE REVIEWS CANCER (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma
S Brennecke et al.
MELANOMA RESEARCH (2005)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis
JY Dong et al.
EMBO JOURNAL (2004)
Share Paper
